四環醫藥：2024年度報告.pdf

1、年度報告ANNUAL REPORTSihuan Pharmaceutical Holdings Group Ltd.四環醫藥控股集團有限公司(incorporated in Bermuda with limited liability)（於百慕達註冊成立之有限公司）Stock Code 股份代號：0460公司簡介CORPORATE PROFILEFounded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010,Sihuan Pharmaceutical Holdings

2、 Group Ltd.(“Sihuan Pharmaceutical”or the“Company”,together with its subsidiaries,the“Group”)(Stock Code:00460.HK)is an international medical aesthetic and biopharmaceutical company led and driven by innovation,with a leading independent production,and research and development(“R&D”)technology platf

3、orm,a rich global product pipeline and a mature and excellent sales system.Focusing on high-growth therapeutic areas such as medical aesthetics,oncology,metabolism,diabetes,cardiovascular and cerebrovascular,modern Chinese medicine and industrial hemp,it adheres to its overall strategic objective of

4、“Adhering to the full-speed promotion of a two-wheeled strategy of Sihuan medical aesthetics and biopharmaceuticals”to build a leading medical aesthetics and biopharmaceutical enterprise in China.四環醫藥控股集團有限公司（四環醫藥 或 本公司，連同其附屬公司為 本集團）（股份代號：00460.HK）創立於二零零一年，二零一零年於香港聯合交易所有限公司主板上市，是一家以創新為引領，堅持創新驅動，擁有獨立

5、領先的自主生產、研究與開發（研發）技術平台，具備豐富的全球化產品管線和成熟卓越銷售體系的國際化醫美及生物製藥企業。四環醫藥聚焦醫美、腫瘤、代謝、糖尿病、心腦血管、現代中藥及工業大麻等高增長治療領域，一直秉承堅持全速推進四環醫美及生物製藥雙輪驅動戰略 的整體戰略目標來打造中國領先的醫美及生物製藥企業。2公司資料Corporate Information4發展里程Milestones16獎項Awards21財務摘要Financial Summary22主席報告Chairmans Statement26管理層討論及分析Management Discussion and Analysis57董事履歷B

6、iographical Details of Directors62企業管治報告Corporate Governance Report88董事會報告Report of Directors目錄CONTENTS115獨立核數師報告Independent Auditors Report122綜合損益及其他全面收益表Consolidated Statement of Profit or Loss and Other Comprehensive Income124綜合財務狀況表Consolidated Statement of Financial Position126綜合權益變動表Consolidat